Strive Asset Management LLC Invests $17.45 Million in IQVIA Holdings Inc. $IQV

Strive Asset Management LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 91,856 shares of the medical research company’s stock, valued at approximately $17,447,000. IQVIA accounts for 0.6% of Strive Asset Management LLC’s portfolio, making the stock its 17th biggest position.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alliancebernstein L.P. raised its holdings in IQVIA by 0.6% in the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after purchasing an additional 19,573 shares during the period. Artisan Partners Limited Partnership grew its holdings in shares of IQVIA by 4.9% during the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after buying an additional 161,085 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after acquiring an additional 581,157 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of IQVIA by 12.3% in the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after purchasing an additional 253,759 shares during the last quarter. Finally, Cantillon Capital Management LLC raised its holdings in shares of IQVIA by 27.3% during the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock worth $366,002,000 after acquiring an additional 413,256 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 2.4%

Shares of IQVIA stock opened at $174.48 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The company’s 50-day simple moving average is $211.19 and its 200-day simple moving average is $208.02. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The firm has a market cap of $29.61 billion, a price-to-earnings ratio of 22.20, a price-to-earnings-growth ratio of 1.72 and a beta of 1.40.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. During the same period last year, the firm earned $3.12 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

IQV has been the topic of several analyst reports. Royal Bank Of Canada started coverage on shares of IQVIA in a research report on Tuesday. They set an “outperform” rating and a $221.00 price target on the stock. TD Cowen raised their price target on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Barclays cut their target price on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Friday, February 6th. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a report on Friday, February 6th. Finally, Mizuho set a $215.00 target price on shares of IQVIA in a research report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $231.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.